+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
4857-06-1,MFCD00051944
Catalog No.:AA003GYX

4857-06-1 | 2-Chlorobenzimidazole

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1g
97%
in stock  
$6.00   $4.00
- +
5g
97%
in stock  
$8.00   $6.00
- +
10g
97%
in stock  
$13.00   $9.00
- +
25g
97%
in stock  
$24.00   $17.00
- +
100g
97%
in stock  
$74.00   $52.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA003GYX
Chemical Name:
2-Chlorobenzimidazole
CAS Number:
4857-06-1
Molecular Formula:
C7H5ClN2
Molecular Weight:
152.5810
MDL Number:
MFCD00051944
SMILES:
Clc1nc2c([nH]1)cccc2
NSC Number:
111358
Properties
Properties
 
BP:
328.5°C at 760 mmHg  
Form:
Solid  
MP:
207-211 °C(lit.)  
Refractive Index:
1.5500 (estimate)  
Stability:
Moisture Sensitive  
Storage:
Room Temperature;Light sensitive;Keep in dry area;  

Computed Properties
 
Complexity:
129  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
10  
Hydrogen Bond Acceptor Count:
1  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
0  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
2.2  

Synonyms
 
  
Upstream Synthesis Route

[1]IndianJournalofChemistry-SectionBOrganicandMedicinalChemistry,2005,vol.44,#6,p.1239-1242

[2]JournalofMedicinalChemistry,2016,vol.59,#15,p.7188-7211

[3]ACSInfectiousDiseases,2017,vol.3,#3,p.225-236

[4]AustralianJournalofChemistry,1982,vol.35,#4,p.775-784

[5]AttidellaAccademiaNazionaledeiLincei,ClassediScienzeFisiche,MatematicheeNaturali,Rendiconti,1900,vol.<5>9II,p.271

[6]ZhurnalObshcheiKhimii,1953,vol.23,p.1691,1694;engl.Ausg.S.1779,1781

[7]Patent:US4314065,1982,A,

[8]Patent:US4096263,1978,A,

[9]BioorganicandMedicinalChemistryLetters,2008,vol.18,#18,p.5010-5014

[10]BioorganicandMedicinalChemistryLetters,2014,vol.24,#4,p.1071-1074

[11]JournalofMedicinalChemistry,2018,vol.61,#19,p.8875-8894

[1]SyntheticCommunications,1996,vol.26,#17,p.3323-3329

[2]JournalofMedicinalChemistry,1986,vol.29,#6,p.1099-1113

[3]JournalofMedicinalChemistry,2011,vol.54,#13,p.4508-4522

[4]JournalofMedicinalChemistry,2012,vol.55,#14,p.6278-6293

[5]JournalofHeterocyclicChemistry,1995,vol.32,#3,p.707-718

[6]Patent:US5461059,1995,A,

[7]Patent:US5149700,1992,A,

[8]Patent:US6756382,2004,B2,

[9]Patent:US2003/144283,2003,A1,

[1]JournaloftheKoreanChemicalSociety,2010,vol.54,#5,p.589-593

[2]JournaloftheChileanChemicalSociety,2012,vol.57,#2,p.1122-1125,4

[1]Patent:US5106857,1992,A,

[1]SyntheticCommunications,1998,vol.28,#9,p.1703-1712

Downstream Synthesis Route

[1]ZhurnalObshcheiKhimii,1953,vol.23,p.1691,1694;engl.Ausg.S.1779,1781

[1]JournalofMedicinalChemistry,1986,vol.29,p.1178-1183

[2]ChemicalandPharmaceuticalBulletin,1999,vol.47,p.1573-1578

[1]Patent:EP2740730,2014,A1.Locationinpatent:Paragraph0320

[2]JournaloftheChemicalSociety.PerkintransactionsII,1985,p.1513-1522

[1]AngewandteChemie-InternationalEdition,2012,vol.51,p.10364-10367

[2]TetrahedronLetters,2016,vol.57,p.1035-1039

[3]Patent:US2011/306613,2011,A1.Locationinpatent:Page/Pagecolumn29

[4]JournaloftheChemicalSociety.PerkintransactionsII,1985,p.1513-1522

[1]PharmaceuticalChemistryJournal,1988,vol.22,p.146-150    Khimiko-FarmatsevticheskiiZhurnal,1988,vol.22,p.195-199

Literature

Title: Cytotoxic activity, X-ray crystal structures and spectroscopic characterization of cobalt(II), copper(II) and zinc(II) coordination compounds with 2-substituted benzimidazoles.

Journal: Journal of inorganic biochemistry 20090901

Title: Functional group interactions of a 5-HT3R antagonist.

Journal: BMC biochemistry 20020101

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 4857-06-1
18227-18-4

18227-18-4

 203302-73-2

203302-73-2
Building Blocks
More >
Historical Records
2060060-78-6

2060060-78-6

 1311139-79-3

1311139-79-3

 62966-77-2

62966-77-2

 2640954-93-2

2640954-93-2
Tags:4857-06-1 Molecular Formula|4857-06-1 MDL|4857-06-1 SMILES|4857-06-1 2-Chlorobenzimidazole
Catalog No.: AA003GYX
4857-06-1,MFCD00051944
4857-06-1 | 2-Chlorobenzimidazole
Pack Size： 1g
Purity： 97%
in stock
$6.00 $4.00
Pack Size： 5g
Purity： 97%
in stock
$8.00 $6.00
Pack Size： 10g
Purity： 97%
in stock
$13.00 $9.00
Pack Size： 25g
Purity： 97%
in stock
$24.00 $17.00
Pack Size： 100g
Purity： 97%
in stock
$74.00 $52.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA003GYX
Chemical Name: 2-Chlorobenzimidazole
CAS Number: 4857-06-1
Molecular Formula: C7H5ClN2
Molecular Weight: 152.5810
MDL Number: MFCD00051944
SMILES: Clc1nc2c([nH]1)cccc2
NSC Number: 111358
Properties
BP: 328.5°C at 760 mmHg  
Form: Solid  
MP: 207-211 °C(lit.)  
Refractive Index: 1.5500 (estimate)  
Stability: Moisture Sensitive  
Storage: Room Temperature;Light sensitive;Keep in dry area;  
Complexity: 129  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 10  
Hydrogen Bond Acceptor Count: 1  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 0  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 2.2  
82:   
Upstream Synthesis Route
615-16-7    4857-06-1 

[1]IndianJournalofChemistry-SectionBOrganicandMedicinalChemistry,2005,vol.44,#6,p.1239-1242

[2]JournalofMedicinalChemistry,2016,vol.59,#15,p.7188-7211

[3]ACSInfectiousDiseases,2017,vol.3,#3,p.225-236

[4]AustralianJournalofChemistry,1982,vol.35,#4,p.775-784

[5]AttidellaAccademiaNazionaledeiLincei,ClassediScienzeFisiche,MatematicheeNaturali,Rendiconti,1900,vol.<5>9II,p.271

[6]ZhurnalObshcheiKhimii,1953,vol.23,p.1691,1694;engl.Ausg.S.1779,1781

[7]Patent:US4314065,1982,A,

[8]Patent:US4096263,1978,A,

[9]BioorganicandMedicinalChemistryLetters,2008,vol.18,#18,p.5010-5014

[10]BioorganicandMedicinalChemistryLetters,2014,vol.24,#4,p.1071-1074

[11]JournalofMedicinalChemistry,2018,vol.61,#19,p.8875-8894

615-16-7    4857-06-1 

[1]SyntheticCommunications,1996,vol.26,#17,p.3323-3329

[2]JournalofMedicinalChemistry,1986,vol.29,#6,p.1099-1113

[3]JournalofMedicinalChemistry,2011,vol.54,#13,p.4508-4522

[4]JournalofMedicinalChemistry,2012,vol.55,#14,p.6278-6293

[5]JournalofHeterocyclicChemistry,1995,vol.32,#3,p.707-718

[6]Patent:US5461059,1995,A,

[7]Patent:US5149700,1992,A,

[8]Patent:US6756382,2004,B2,

[9]Patent:US2003/144283,2003,A1,

463-73-0    95-54-5    4857-06-1 

[1]JournaloftheKoreanChemicalSociety,2010,vol.54,#5,p.589-593

[2]JournaloftheChileanChemicalSociety,2012,vol.57,#2,p.1122-1125,4

615-16-7    4857-06-1 

[1]Patent:US5106857,1992,A,

40828-54-4    4857-06-1 

[1]SyntheticCommunications,1998,vol.28,#9,p.1703-1712

Downstream Synthesis Route
4857-06-1    506-59-2    2851-13-0 

[1]ZhurnalObshcheiKhimii,1953,vol.23,p.1691,1694;engl.Ausg.S.1779,1781

4318-37-0    4857-06-1    101953-62-2 

[1]JournalofMedicinalChemistry,1986,vol.29,p.1178-1183

[2]ChemicalandPharmaceuticalBulletin,1999,vol.47,p.1573-1578

4857-06-1    124-40-3    2851-13-0 

[1]Patent:EP2740730,2014,A1.Locationinpatent:Paragraph0320

[2]JournaloftheChemicalSociety.PerkintransactionsII,1985,p.1513-1522

4857-06-1    74-89-5    17228-38-5 

[1]AngewandteChemie-InternationalEdition,2012,vol.51,p.10364-10367

[2]TetrahedronLetters,2016,vol.57,p.1035-1039

[3]Patent:US2011/306613,2011,A1.Locationinpatent:Page/Pagecolumn29

[4]JournaloftheChemicalSociety.PerkintransactionsII,1985,p.1513-1522

4857-06-1    107-07-3    40019-65-6 

[1]PharmaceuticalChemistryJournal,1988,vol.22,p.146-150    Khimiko-FarmatsevticheskiiZhurnal,1988,vol.22,p.195-199

Literature fold

Title: Cytotoxic activity, X-ray crystal structures and spectroscopic characterization of cobalt(II), copper(II) and zinc(II) coordination compounds with 2-substituted benzimidazoles.

Journal: Journal of inorganic biochemistry20090901

Title: Functional group interactions of a 5-HT3R antagonist.

Journal: BMC biochemistry20020101

Related Products of of 4857-06-1
18227-18-4
18227-18-4
203302-73-2
203302-73-2
Building Blocks More >
19523-57-0
19523-57-0
2-Ethoxy-1-naphthaldehyde
AA003H2Y | MFCD00046427
170981-26-7
170981-26-7
2-Fluoro-4-methylphenylboronic acid
AA003H6U | MFCD05664239
629-56-1
629-56-1
2-Hexadecenoic acid
AA003HA7 | MFCD00045907
89487-91-2
89487-91-2
2-Iodo-4-nitrophenol
AA003HDS | MFCD01165664
6609-56-9
6609-56-9
2-Methoxybenzonitrile
AA003HH1 | MFCD13182120
939-83-3
939-83-3
2-Methyl-5-nitrobenzonitrile
AA003HKW | MFCD00017040
7498-57-9
7498-57-9
2-Naphthylacetonitrile
AA003HOY | MFCD00004122
53641-60-4
53641-60-4
2-Phenylglycinonitrile HCl, tech grade
AA003HSQ | MFCD00013022
2403-66-9
2403-66-9
2-(3-Hydroxypropyl)benzimidazole
AA003HWI | MFCD00022688
69963-46-8
69963-46-8
3-(3-Pyridyl)-2-propen-1-ol
AA003HZT | MFCD03425627
Historical Records
2060060-78-6
2060060-78-6
1311139-79-3
1311139-79-3
62966-77-2
62966-77-2
2640954-93-2
2640954-93-2
Submit
© 2017 AA BLOCKS, INC. All rights reserved.